Articles tagged "Immunosuppression"

2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…
2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
A. Sharfuddin, M. Yaqub, D. Mishler, W. Goggins, T. Taber, O. Adebiyi.
Division of Renal Disease and Hypertension, Indiana University Health Transplant Program, Indianapolis, IN.
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…
2018 American Transplant Congress
Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study
J. Motter,¹ A. Massie,¹ J. Garonzik Wang,¹ K. Jackson,¹ X. Luo,¹ A. Muzaale,¹ B. Orandi,² D. Segev.¹
¹JHU, Baltimore; ²UCSF, San Francisco.
Background: Many patients with a willing, but incompatible live donor choose to undergo incompatible live donor kidney transplantation (ILDKT) facilitated by desensitization procedures to eliminate…
2018 American Transplant Congress
Evaluation of MPA Dose on Development of DSA Following Pancreas Transplant
J. Descourouez,¹ M. Jorgenson,¹ A. Twigg,¹ G. Leverson,² J. Odorico,³ R. Redfield.³
¹Pharmacy, UW Health, Madison, WI; ²Surgery, UW Health, Madison, WI; ³Transplantation, UW Health, Madison, WI.
The relationship between mycophenolate (MPA) dose and the development of donor specific antibody (DSA) following pancreas transplant has not been elucidated. This study evaluates the…
2018 American Transplant Congress
Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and Their Influence on Tacrolimus Pharmacokinetics in Renal Transplant Recipients
Z. Wang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu.
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Tacrolimus (TAC) is an established essential immunosuppressive agent for renal transplant recipients. Our study aims to investigate the pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19…
2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss,¹ J. Goebel,² M. Bock.²
¹Pharmacy, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…
2018 American Transplant Congress
Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function
S. Sethi, J. Choi, A. Vo, R. Najjar, A. Peng, S. Jordan, E. Huang.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Belatacept was shown to have longer kidney graft survival and higher eGFR at 7 years than a calcineurin inhibitor (CNI)-based regimen in the BENEFIT…
2018 American Transplant Congress
Cognition after Belatacept Conversion
C. Ogbejesi, E. Cohen, K. Belfield, W. Asch.
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…
2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Regulation of NK Cell Cytotoxicity by TEC Expression of Clr Proteins in Kidney Ischemia Reperfusion Injury (IRI)
B. Fuhrmann,^1,5 D. Lian,⁵ Z. Yin,⁵ S. Ma,^4,5 J. Arp,⁵ Z. Zhang,^2,3,4,5 A. Jevnikar.^1,3,4,5
¹Microbiology and Immunology, Western University, London, Canada; ²Pathology, Western University, London, Canada; ³Medicine, Western University, London, Canada; ⁴Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada; ⁵Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, Canada.
Background: Kidney tubular epithelial cells (TEC) may negatively regulate NK cell activation and cytotoxic capacity by surface expression of a novel class of C-type lectin-related…